Theleme Partners LLP Has $205.32 Million Position in Moderna, Inc. $MRNA

Key Points

• Theleme Partners LLP has trimmed its stake in Moderna, Inc., making it the firm's largest holding, accounting for approximately 16.1% of its investment portfolio.
• Several institutional investors, including Deseret Mutual Benefit Administrators and Parallel Advisors LLC, have recently increased their positions in Moderna during the 1st quarter of the year.
• Moderna reported a loss of $2.13 earnings per share in its most recent quarterly earnings, which was better than analysts' expectations, despite a 41.1% decline in revenue year-over-year.

Theleme Partners LLP cut its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 0.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,242,390 shares of the company's stock after selling 64,471 shares during the period. Moderna accounts for about 16.1% of Theleme Partners LLP's investment portfolio, making the stock its biggest position. Theleme Partners LLP owned 1.87% of Moderna worth $205,322,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. boosted its position in Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after buying an additional 877,162 shares in the last quarter. Northern Trust Corp boosted its position in Moderna by 5.4% in the first quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock valued at $88,441,000 after buying an additional 160,572 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after buying an additional 285,662 shares in the last quarter. Voloridge Investment Management LLC boosted its position in Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after buying an additional 1,996,003 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Moderna by 1.8% in the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after buying an additional 34,034 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Price Performance

MRNA traded down $1.78 during mid-day trading on Friday, hitting $23.61. The stock had a trading volume of 20,863,563 shares, compared to its average volume of 10,794,489. The stock's fifty day simple moving average is $28.48 and its 200-day simple moving average is $28.28. The firm has a market capitalization of $9.19 billion, a price-to-earnings ratio of -3.13 and a beta of 1.93. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $75.37.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period last year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Barclays reduced their price target on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research report on Monday, August 4th. William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Bank of America reduced their target price on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research report on Tuesday, July 22nd. JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a research report on Friday, August 1st. Finally, Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $42.88.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.